Raykol Group Secures Over RMB 100 Million Series A Funding Led by Sunshine Ronghui Capital

VCBeat (WeChat ID: vcbeat) has learned that Raykol Group (Xiamen) Co., Ltd. (“Raykol Group”) recently announced the completion of its Series A financing round, raising over RMB 100 million. The round was led by Riverhead Capital (RHC), with Sherpa Healthcare Partners participating as a co-investor. Following this financing, Raykol Group will continue to increase its R&D investment, expand its product portfolio covering automated pre-treatment equipment for life sciences, multi-functional preparation workstations, and reagents and consumables, and strengthen product development and technological upgrades in the field of life science automation to meet broad market demand.

Reeko Group currently comprises six subsidiaries, one research institute, and three R&D bases, with a workforce of over 500 full-time employees. The company has established a closed-loop development process spanning market research, product definition, R&D, and pre-sales and after-sales support, thereby building a robust operational support system. Its products enjoy high market recognition, an excellent reputation, and strong capabilities in iterative upgrades. Currently, Reeko Group’s sales network covers China and extends to overseas markets. Its products are widely applied in fields such as pharmaceutical testing, life sciences, healthcare, environmental monitoring, food testing, agricultural product testing, disease control systems, and national defense emergency response. The company’s product technology standards and market share rank among the industry leaders.

Raykol Group's Business Layout

 Raykol Group's Service Areas

Reeko Group, established in 2010, is a developer of one-stop laboratory automation solutions in China and a national high-tech enterprise integrating R&D, production, sales, and third-party testing services. Starting with automated pre-treatment technologies for chemical analysis, Reeko Group leverages automated standalone modules, machine vision, and motion control technology to provide fully integrated workstations, offering modular and intelligent application solutions for the fields of laboratory automation and smart laboratories.

Since the launch of its first-generation fully automated solid-phase extraction instrument in 2010, the organic sample preparation product line has covered the entire automated workflow, including sample preparation, sample extraction, extract purification, and concentration with volume adjustment. The core product portfolio comprises more than ten categories, such as solid-phase extraction, pressurized fluid extraction, fully automated homogenizers, parallel concentrators, and nitrogen blow-down concentrators, which have been widely recognized by customers.

In early 2022, the company strengthened its inorganic sample preparation capabilities through the acquisition and integration of Shanghai Xintuo, thereby securing a complete product line for wet digestion, including microwave digesters, graphite digesters, and automatic titrators.

Raykol Laboratory Automation Equipment

In 2019, the company launched the ISP series of multi-functional sample preparation workstations. Built on a sophisticated multi-axis robotic platform, this product line integrates up to 30 modules, including sample management, liquid handling, cap opening/closing, oscillatory extraction, and centrifugal separation. This integration enables unmanned sample preparation, requiring personnel only to perform simple tasks such as sample preparation and weighing. Consequently, it significantly reduces human-induced variability in the sample preparation process, alleviates the workload of laboratory staff, and achieves a high-throughput, fully automated, highly precise, and safe end-to-end sample preparation workflow.

Rayco Automated Integrated Workstation

The company develops automated biological sample preparation equipment, serving fields such as biological/pharmaceutical analysis, molecular diagnostics, clinical testing, genomics, proteomics, and metabolomics. It has officially launched a range of life science sample preparation instruments, including fully automatic nucleic acid extraction and purification systems, PCR setup systems, library preparation workstations, fully automatic proteomics sample preparation workstations, liquid handling workstations, aliquoting systems, dried blood spot punchers, biochip spotting systems, and clinical mass spectrometry sample preparation systems.

 Raykol Life Sciences Laboratory Automation Products

Mr. Lin Zhijie, Chairman of Ruike GroupHe expressed sincere gratitude to RHC and Sherpa for their recognition and support of Raykol Group. After more than a decade of development and accumulation, Raykol Group has completed its first market-oriented financing round. Leveraging this capital support, we will continue to stay at the technological forefront in laboratory automation, consolidate our leading position in pre-antical sample preparation for physicochemical analysis, aggressively expand into the life sciences sector, strengthen our product portfolio, and build an industrial closed loop that covers all scenarios in physicochemical and life sciences fields, as well as all elements including equipment and consumables, aiming to become a globally leading provider of comprehensive laboratory solutions.

Mr. Shi Shenghao, Partner at RHCRHC stated that it is honored to participate in Reeko Group's first round of financing. RHC closely monitors the development opportunities for domestically produced scientific instruments and the substantial demand for laboratory automation upgrades. With over a decade of deep engagement in this field, Reeko Group has established a comprehensive, closed-loop product portfolio and earned high recognition from its customers. We look forward to the company further expanding its application scenarios and delivering higher-quality products and services to the market!

Sherpa Investment Director Zhang ZhenyuIt was stated that domestically produced scientific instruments and the field of laboratory automation hold immense commercial potential and social value. In this direction, we observe that Raykol Group has established a solid strategic footprint. Starting with individual physicochemical analysis products, the company has gained customer recognition and secured a significant market share in the area of automated sample pre-treatment. Meanwhile, the company is continuously enriching its product portfolio, upgrading and iterating its laboratory automation solutions, and constantly expanding the boundaries of application scenarios. Sherpa is honored to participate in this round of financing and looks forward to Raykol’s contributions to advancing the development of domestically produced scientific instruments.

RHC was established in January 2015 as one of the first private equity fund management companies in China’s insurance industry to be initiated and set up with insurance capital. Since its inception, RHC has built its team according to market-oriented and professional standards, focusing on the healthcare and emerging industries sectors. It targets niche segments critical to national supply chain security (“chokepoint” areas) and invests in “Specialized, Refined, Differential, and Innovative” (SRDI) enterprises characterized by high technological innovation. The company manages assets totaling RMB 30 billion, has invested in over 70 companies, and facilitated IPOs for 16 of them. Notable portfolio companies include Sirnaomics (the first listed nucleic acid drug company in China), Lepu Biopharma (a leader in ADCs), Ingston Biology (a pioneer in one-stop clinical mass spectrometry solutions in China), Silicon Based Bionics (the first domestic enterprise to launch a 14-day calibration-free CGM), TopAll Therapeutics (a developer of original natural fully human monoclonal antibody new drugs), Care Medical (a manufacturer of domestically produced autonomous hollow fiber membranes for dialysis), Qitan Technology (the only domestic enterprise to have completed a prototype for fourth-generation nanopore sequencing), SenseTime (one of the “AI Four Dragons”), Enflame Technology (a leader in training and inference chips), InnoGrit Technology (a leader in storage chips), Moore Threads (a leader in domestic GPU chips), Dream Ink (a globally leading flexible electronic interaction technology innovation platform), Helmholtz (a leading domestic provider of automotive-grade thin-film heaters), and Shuocheng Technology (a leading domestic enterprise in noise identification and predictive maintenance). These investments have generated substantial returns for investors.

Sherpa is a specialized fund focused on healthcare investment, adhering to an investment philosophy centered on building industry ecosystems. Based on deep insights into the treatment of major diseases, Sherpa constructs its portfolio to address rigid, unmet medical needs, with strategic investments spanning the entire industrial value chain, both upstream and downstream. By actively sharing operational expertise and forward-looking perspectives across the full industry chain with portfolio companies, the team proactively fosters internal and external synergy, helping enterprises achieve rapid growth in business performance and valuation, while securing leading positions in their respective niche markets. Sherpa has invested in industry leaders across segments such as medical services, pharmaceuticals, gene technology, and medical devices, establishing comprehensive resource advantages in deal sourcing, post-investment value-added services, and exit strategies. From 2011 to 2021, through four fund vintages and the refinement of over 100 healthcare projects, Sherpa has had the privilege of partnering with numerous outstanding entrepreneurs, growing together along the journey.